Skip Navigation Links.
Collapse <span class="m110 colortj mt20 fontw700">Volume 12 (2024)</span>Volume 12 (2024)
Collapse <span class="m110 colortj mt20 fontw700">Volume 11 (2023)</span>Volume 11 (2023)
Collapse <span class="m110 colortj mt20 fontw700">Volume 10 (2022)</span>Volume 10 (2022)
Collapse <span class="m110 colortj mt20 fontw700">Volume 9 (2021)</span>Volume 9 (2021)
Collapse <span class="m110 colortj mt20 fontw700">Volume 8 (2020)</span>Volume 8 (2020)
Collapse <span class="m110 colortj mt20 fontw700">Volume 7 (2019)</span>Volume 7 (2019)
Collapse <span class="m110 colortj mt20 fontw700">Volume 6 (2018)</span>Volume 6 (2018)
Collapse <span class="m110 colortj mt20 fontw700">Volume 5 (2017)</span>Volume 5 (2017)
Collapse <span class="m110 colortj mt20 fontw700">Volume 4 (2016)</span>Volume 4 (2016)
Collapse <span class="m110 colortj mt20 fontw700">Volume 3 (2015)</span>Volume 3 (2015)
Collapse <span class="m110 colortj mt20 fontw700">Volume 2 (2014)</span>Volume 2 (2014)
Collapse <span class="m110 colortj mt20 fontw700">Volume 1 (2013)</span>Volume 1 (2013)
American Journal of Medical Case Reports. 2019, 7(10), 244-249
DOI: 10.12691/AJMCR-7-10-6
Case Report

Longitudinally Extensive Transverse Myelitis Associated With Systemic Lupus Erythematosus: A Case Report and Literature Review

Talha Mehmood1, Irsa Munir1, Madina Abduraimova1, Miguel Antonio Ramirez1, Sunny Paghdal1 and Isabel M. McFarlane1,

1Department of Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY 11203 USA

Pub. Date: July 31, 2019

Cite this paper

Talha Mehmood, Irsa Munir, Madina Abduraimova, Miguel Antonio Ramirez, Sunny Paghdal and Isabel M. McFarlane. Longitudinally Extensive Transverse Myelitis Associated With Systemic Lupus Erythematosus: A Case Report and Literature Review. American Journal of Medical Case Reports. 2019; 7(10):244-249. doi: 10.12691/AJMCR-7-10-6

Abstract

Background: Lupus myelitis is a rare but disastrous complication of systemic lupus erythematosus (SLE). The transverse myelitis (TM) may involve three or more contiguous spinal cord segments and as such is designated longitudinally extensive transverse myelitis (LETM). The neurological presentation may vary based on the location of the pathology and may consist of a combination of sensory and motor deficits. TM could be the presenting feature of SLE or present after 10 years of disease, while SLE was considered to be in remission. Case presentation: 26-year-old Black man with history of biopsy proven-lupus nephritis that had progressed to ESRD, presented with sudden onset quadriplegia that resolved upon arrival to the hospital. On exam, the temperature was 101.8°F and the neurological exam was consistent with residual weakness on the left sided-upper and lower extremities. Leukopenia, lymphopenia and thrombocytopenia, along with low complements were noted. Brain MRI was normal however, the spine MRI was suspicious for an epidural process (C2-T4) and intravenous antibiotics were commenced. After five days, neurological improvement was nil and new spine MRI revealed spinal cord edema secondary to myelitis at several spinal cord levels (C2-T4). Laboratory data was consistent with a SLE flare complicated with longitudinal extensive transverse myelitis. Pulse steroids and plasma exchange were initiated. Two weeks after admission, MRI demonstrated resolution of the epidural spinal lesion and marked improvement in spinal cord edema. Conclusion: TM can be the presenting feature of SLE or appear later on during the course of their disease. LETM is the most frequently type of TM found among SLE patients. Given the grave nature of the disease, it is of paramount importance that clinical features of TM be promptly recognized among SLE patients, to prevent catastrophic or even life-threatening outcomes.

Keywords

systemic lupus erythematosus, transverse myelitis, longitudinal extensive transverse myelitis, neuromyelitis optica spectrum disorders, aquaporin 4 antibodies, seronegative NMOSD, autoimmune disease

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  Futrell N, Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke. 1989 May; 20(5): 583-91.
 
[2]  Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. InSeminars in arthritis and rheumatism 2011 Oct 1 (Vol. 41, No. 2, pp. 203-211). WB Saunders.
 
[3]  Almoallim H, Bukhari M, Alwafi L, Wali G. Transverse myelitis as a presenting feature of late onset systemic lupus erythematosus. Annals of Saudi medicine. 2009 Mar 1; 29(2): 156.
 
[4]  Mok CC, Lau CS, Chan EY, Wong RW. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. The Journal of rheumatology. 1998 Mar; 25(3): 467-73.
 
[5]  Zahid AS, Mubashir A, Mirza SA, Naqvi IH, Talib A. Systemic Lupus Erythematosus Presenting as Longitudinally Extensive Transverse Myelitis and Nephritis: A Case Report. Cureus. 2018 Apr; 10(4).
 
[6]  Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. InSeminars in arthritis and rheumatism 2010 Feb 1 (Vol. 39, No. 4, pp. 257-268). WB Saunders.
 
[7]  Tench CM, McCurdie I, White PD, d'Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology. 2000 Nov 1; 39(11): 1249-54.
 
[8]  Greco CM, Rudy TE, Manzi S. Adaptation to chronic pain in systemic lupus erythematosus: applicability of the multidimensional pain inventory. Pain medicine. 2003 Mar 1; 4(1): 39-50.
 
[9]  Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA L XIV, a multiethnic US cohort. Rheumatology. 2009 Feb 20; 48(5): 542-5.
 
[10]  Miner JJ, Kim AH. Cardiac manifestations of systemic lupus erythematosus. Rheumatic Disease Clinics. 2014 Feb 1; 40(1): 51-60.
 
[11]  Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. The Journal of rheumatology. 1992 Jan; 19(1): 47-52.
 
[12]  Espinosa G, Mendizábal A, Mínguez S, Ramo-Tello C, Capellades J, Olivé A, Cervera R. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. InSeminars in arthritis and rheumatism 2010 Feb 1 (Vol. 39, No. 4, pp. 246-256). WB Saunders.
 
[13]  Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Annals of the Rheumatic Diseases. 2000 Feb 1; 59(2): 120-4.
 
[14]  Li XY, Xiao P, Xiao HB, Zhang LJ, Pai P, Chu P, Chan TM. Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity. Lupus. 2014 Oct; 23(11): 1178-86.
 
[15]  Nardone R, Fitzgerald RT, Bailey A, Zuccoli G. Longitudinally extensive transverse myelitis in systemic lupus erythematosus: case report and review of the literature. Clinical neurology and neurosurgery. 2015 Feb 1; 129: 57-61.
 
[16]  Andrianakos AA, Duffy J, Suzuki M, Sharp JT. Transverse myelopathy in systemic lupus erythematosus: report of three cases and review of the literature. Annals of internal medicine. 1975 Nov 1; 83(5): 616-24.
 
[17]  D'Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J, Khamashta MA, Hughes GR. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. The Journal of rheumatology. 2004 Feb 1; 31(2): 280-5.
 
[18]  Espinosa G, Mendizábal A, Mínguez S, Ramo-Tello C, Capellades J, Olivé A, Cervera R. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. InSeminars in arthritis and rheumatism 2010 Feb 1 (Vol. 39, No. 4, pp. 246-256). WB Saunders.
 
[19]  Kitley J, Leite MI, Küker W, Quaghebeur G, George J, Waters P, Woodhall M, Vincent A, Palace J. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA neurology. 2013 Nov 1; 70(11): 1375-81.
 
[20]  Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, et al. (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177-189.
 
[21]  Li XY, Xiao P, Xiao HB, Zhang LJ, Pai P, Chu P, Chan TM. Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity. Lupus. 2014 Oct; 23(11): 1178-86.
 
[22]  Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, Cacoub P, Vital-Durand D, Hot A, Tebib J, Aumaitre O, Schleinitz N. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus. 2015 Jan; 24(1): 74-81.
 
[23]  Duarte AC, Sousa S, Nunes T, Cordeiro A, Gonçalves P. Intravenous human immunoglobulin for the treatment of severe longitudinal extensive transverse myelitis associated with systemic lupus erythematous. Acta reumatologica portuguesa. 2018; 43(2): 154-5.
 
[24]  Furtado I, Pinheiro G, Campar A, Mendonça T. Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge. BMJ case reports. 2018 Jun 4; 2018: bcr-2017.
 
[25]  Bhat A, Naguwa S, Cheema G, Gershwin ME. The epidemiology of transverse myelitis. Autoimmunity Reviews. 2010 Mar 1; 9(5): A395-9.
 
[26]  Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, Cacoub P, Vital-Durand D, Hot A, Tebib J, Aumaitre O, Schleinitz N. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus. 2015 Jan; 24(1): 74-81.